読み込み中
NASDAQHealthcareMedical - Pharmaceuticals
最新データ
$79.24
−$0.54 · -0.68%
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
終値時点
$79.24
−$0.54 · -0.68%
時間外
$79.24
$0.00 · 0.00%
10月12日 16:38 ET
日中の時刻はETです。市場データは遅延する場合があります。
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
日中レンジ
現在 $79.24
52週レンジ
現在 $79.24
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
79
割安
センチメント
66
強気
リスク
31
中程度のリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
日中レンジ
現在 $79.24
52週レンジ
現在 $79.24
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6.78億 USD | 4.23億 USD | 2.7億 USD | 2.2億 USD | 3854.4万 USD |
| 売上原価 | 3.07億 USD | 6091万 USD | 5652.4万 USD | 2289.5万 USD | 910万 USD |
| 粗利益 | 3.7億 USD | 3.62億 USD | 2.14億 USD | 1.97億 USD | 2944.4万 USD |
| 研究開発 | 9685.3万 USD | 1.12億 USD | 7609.7万 USD | 6549万 USD | 9929.7万 USD |
| 販売・一般管理 | 1.96億 USD | 1.68億 USD | 1.29億 USD | 9795.1万 USD | 8594.8万 USD |
| 営業費用 | 2.93億 USD | 4.08億 USD | 2.39億 USD | 1.88億 USD | 1.86億 USD |
| 受取利息 | 1164.7万 USD | 946.4万 USD | 854.4万 USD | 125.3万 USD | 9.7万 USD |
| 減価償却費と償却費 | 155.4万 USD | 169.5万 USD | 234.1万 USD | 240.2万 USD | 235.5万 USD |
| 営業利益 | 7722.1万 USD | −4561.6万 USD | −2519.6万 USD | 977.3万 USD | −1.57億 USD |
| 純利益 | 5900.5万 USD | −4319.3万 USD | 1408.4万 USD | 1.83億 USD | −1.58億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.04億0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM9497.63万0.12%787.4億 USD0.19%$277.88-0.38%
Vanguard Morningstar Small-Cap ETFVB7534.7万0.04%1853億 USD0.03%$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK4338.65万0.09%447億 USD0.05%$340.88-1.12%
iShares Russell 2000 Growth ETFIWO3366.5万0.24%139.17億 USD0.24%$353.71-0.86%
Dimensional - US Small Cap ETFDFAS2555.02万0.08%338.69億 USD0.31%$78.17-0.23%
Vanguard Russell 2000 ETFVTWO1915.77万0.10%180億 USD0.06%$112.27-0.35%
Dimensional - US Core Equity 2 ETFDFAC1248.22万0.01%885.96億 USD0.21%$45.31-0.04%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWODimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
